Sentences with phrase «target breast cancer research»

«In the true sense of encouraging the field, we do want to target breast cancer research,» she said last week.

Not exact matches

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

The probes targeted to breast cancer have shown great promise so far in breast cancer clinical trials, and Mankoff and his Penn Medicine colleagues have helped lead this research effort.

«Our research suggests that hnRNPM could be an effective target to stop cancer cells from spreading,» said Northwestern Medicine scientist Chonghui Cheng, M.D. «So far there isn't a really good target that can cure breast cancer.

The audience will learn about the current state of breast cancer research, how data generated by NGS gene panels target variants of interest and have been developed and used in routine laboratory research, and the broader issues of breast cancer education, awareness, and community services.

turned into 10 years of systematic research to identify the enzyme PLK4 as a promising therapeutic target and develop a small molecule inhibitor to block it,» says Dr. Mak, Director of The Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, University Health research to identify the enzyme PLK4 as a promising therapeutic target and develop a small molecule inhibitor to block it,» says Dr. Mak, Director of The Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre, University Health Research at the Princess Margaret Cancer Centre, University Health Network.

According to Dr. Irie, the research is especially important because it supports the potential therapeutic value of targeting PTK6 in ER + breast cancers, which constitute the most common subtype of breast cancer.

The treatment is promising enough that research teams around the world are developing similar stem cell therapies that can target and eradicate cancers of the prostate, lung, breast, skin and other tissues.

New research by scientists at the Pennsylvania Cancer and Regenerative Medicine Research Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breastresearch by scientists at the Pennsylvania Cancer and Regenerative Medicine Research Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breast cCancer and Regenerative Medicine Research Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breastResearch Center, a division of the Baruch S. Blumberg Institute, shows that medicines currently used in HIV treatment may help to target chemotherapy for breast cancercancer.

Robin's research is focused on the genetic regulation of metastasis, primarily in breast cancer and is aimed at identifying new targets for molecular based therapy for patients with progressive disease.

Research suggests a possible specific target for drugs fighting the most common type of breast cancer.

Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cCancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast ccancer, the most aggressive form of breast cancercancer.

She has also obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireBreast Cancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireBreast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Direbreast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Direbreast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Direcancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Diresearch projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireBreast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DireCancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, DiResearch Excellence (SPORE; Carlos Arteaga, Director).

The Department of Translational Research hosts 5 technological platforms (Genomics, Protein arrays, High - content screening, Experimental radiotherapy and Preclinical investigation), 4 labeled teams (resistance to therapy in breast cancers, translational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative breast cancers).

In this past year, 69 % of cause related spending went to research and fellowship grants including a joint investment with the Canadian Institutes of Health Research (CIHR) of $ 6 million specifically targeting breast cancer in youresearch and fellowship grants including a joint investment with the Canadian Institutes of Health Research (CIHR) of $ 6 million specifically targeting breast cancer in youResearch (CIHR) of $ 6 million specifically targeting breast cancer in young women

Tags for this Online Resume: Biotechnology, Diagnostic, Pharmaceutical, Marketing, Oncology, Strategy, Brand Planning, Global Marketing, New Product Planning, Pricing, Market Research, Brand Leader, Commercial, Commercialization, Launch, Drug Development, Matrix, Cross Functional, Digital, KOL, Key Opinion Leader, Portfolio, Management, Brand Team, Agency, Diabetes, Cardiovascular, Commercial Strategy, Corporate Affairs, Communications, Hematology, Urology, Neuroscience, phase 2, phase 3, phase II, phase III, Powerpoint, Excel, Word, Part B, Part D, Seattle, Portland, San Francisco, Executive Director, Senior Director, Director, Vice President, Go - To - Market, Value Proposition, Go To Market, Launch Planning, Access, Reimbursement, Payer, Market Development, Market Assessment, Pipeline, In - Line, Brand Management, Coaching, Leadership, Marketing Strategies, Marketing Strategy, Strategic Planning, Autoimmune, Early Stage, Pre-Launch, Pre Launch, Regulatory, Operations, Marketing Plan, Business Plan, Business Development, Market Analysis, Segmentation, Targeting, Companion Diagnostic, Target Product Profile, Pre-Clinical, Competition, Positoning, Branding, Sales, Budget, Sales Management, Communication Plan, Publication Plan, Project Management, Genetic, Genomic, Lifecycle, Long Range, Device, Late Stage, Direct Report, Indirect Report, New Molecular Entities, Competitive, Biopharmaceutical, Medical Device, Non-Promotional, Tactical, Execution, IND, Revenue, Partner, Clinical, Consult, Analytical, Problem Solver, Global, International, Affordable Care Act, Lymphoma, Leukemia, Prostate, Breast, Cancer, OPDP, Promotional, Promotions, Brand, Healthcare, Distribution, Infrastructure, IMS, Priority Review, Experienced, Patient, Consumer